Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Lucia Bolea, Alejandro Luna, Enrique Blanco, Valentín García Gutiérrez, Sr., Anabelle Chinea, Begoña Hijono, Maria Luisa Palacios-Berraquero, Pablo Palomo Rumschisky, Blanca De Felipe, Lucía Pérez-Lamas, Carlos Jiménez, Beatriz Astibia Mahillo, Alejandro Zurdo-Castronuño, Maria Piñero, Rut Corrales, Pilar Herrera, Javier López

Blood (2024) 144 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2024-206026

Published: 2024

Journal Articles

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Claudia Nuñez-Torron stock, Carlos Jiménez, Fernando Martín Moro, Juan Marquet, Miguel Piris-Villaespesa, Clara Lopez Hernandez, Alejandro Luna, Valentín García Gutiérrez, Sr., Anabelle Chinea, Maria Gemma Moreno Jimenez, Javier López, Pilar Herrera Puente

Blood (2024) 144 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2024-210576

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

Danny Luan, Roni Shouval, Teng Fei, Efrat Luttwak, Alejandro Luna, Magdalena Corona, Maria Lia Palomba, Allison Parascondola, Michael Scordo, Gunjan L. Shah, Susan DeWolf, Miguel-Angel Perales

Blood (2023) 142 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2023-184909

Published: 2023

Journal Articles

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2023-179641

Published: 2023

Journal Articles

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2023) 142 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2023-187783

Published: 2023

Journal Articles

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2023-187240

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

NARROW

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only